A new minireview has been published:

Zeitlinger MA, Derendorf H, Mouton JW, Cars O, Craig WA, Andes D, Theuretzbacher U.:
Protein binding - do we ever learn? Antimicrob Agents Chemother. 2011 May 2

A new article has been published:

Gonzalez D, Conrado DJ, Theuretzbacher U, Derendorf H.:
The Effect of Critical Illness on Drug Distribution. Curr Pharm Biotechnol. 2011 May 10

A new review has been published:

Mouton JW, Ambrose PG, Canton R, Drusano GL, Harbarth S, Macgowan A, Theuretzbacher U, Turnidge J.:
Conserving antibiotics for the future: New ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective.
Drug Resist Updat. 2011 Mar 25.

ICAAC 2011: Workshops at the 51st ICAAC will be held on Friday, September 16, 2011 at the McCormick Place Chicago

ISAP Workshops:

51-01 Basics of Pharmacokinetics and Pharmacodynamics of Anti-Infective Agents
Faculty:
William A. Craig, MD; Emeritus Professor of Medicine; Univ. of Wisconsin, Madison, WI.
Hartmut Derendorf, PhD; Professor; Univ. of Florida, Gainesville, FL.
Alasdair MacGowan, MD; Professor; Bristol Ctr. for Antimicrobial Res., Bristol, United Kingdom.
Johan W. Mouton, PhD; Professor; Radboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands.
Ursula Theuretzbacher, PhD; Principal; Ctr. for Anti-Infective Agents, Vienna, Austria

51-02 Clinical Relevance of Pharmacokinetics and Pharmacodynamics of Anti-Infective Agents
Faculty:
David R. Andes, MD; Associate Professor of Medicine; Univ. of Wisconsin, Madison, WI.
Paul G. Ambrose, PharmD; Director; Ordway Res. Inst., Latham, NY.
Johan W. Mouton, PhD; Professor; Radboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands.
Ursula Theuretzbacher, PhD; Principal; Ctr. for Anti-Infective Agents, Vienna, Austria.
Paul M. Tulkens, MD; Professor; Univ. Louvain, Bruxelles, Belgium.
Markus Zeitlinger, MD; Professor; Med. Univ. Vienna, Vienna, Austria

The proposal for a symposium at ECCMID 2011 - submitted by Ursula Theuretzbacher - has been accepted by ESCMID.

ECCMID 2011, May, 7-10, 2011, Milano, Italy

Bridging the gap of innovation – what we all could do

arranged with the ESCMID PK/PD of Anti-Infectives Study Group (EPASG) and the ISC Working Group: Antimicrobials of the Future

* Antibacterial pipelines – what to expect in the future (U. Theuretzbacher)
* Political processes for the global need for effective antibiotics – moving towards concerted action (O. Cars)
* New ways of using old and coming antibiotics (J. Mouton)
* Improving usage by guidelines – the European experience (P. Tulkens)

Ursula Theuretzbacher has been invited to present at the conference:

Resistance is Futile: The Challenge of Antibacterial Drug Development - Integrating of Chemistry and Biology
April 12-13, 2011 in San Diego, CA

PK/PD in the Drug Development Process -- Learning from Mistakes

How Resistance will Shape the Antibacterial Drug Development Process (Breakfast discussion)

The preclinical and early clinical PK assessment as well as PD studies provide the input for in vitro and in vivo PK/PD models that evaluate exposure-effect relationships. Such PK/PD models are powerful tools for human dose selection, for determining susceptibility breakpoints as well as strategies to mitigate resistance development. Recent late stage clinical failures illustrate the importance of understanding the impact of PKs such as protein binding and concentrations at infection sites and incorporating them early into adequate PK/PD evaluations.

Challenges in the antibacterial market
Resistance demands action

Interview in medical journal: Antibiotika kurz und hoch dosieren

ASM press conference at ICAAC 2010:

press release

Ursula Theuretzbacher has been invited to contribute to the conference 'The Global Need for Effective Antibiotics-Moving towards Concerted Action' in Uppsala, Sweden.

At a historic three day conference at Uppsala University, Sweden, 190 delegates representing 45 countries and many leading stake holders - civil society, academia, industry, governments, authorities, supranational organizations - agreed to turn a new page and move towards concerted action on antibiotic resistance.

The conference builds on discussions held at the expert Swedish EU Presidency meeting “Innovative Incentives for Effective Antibacterials” in September 2009. The participants consist of 150-200 invited researchers, policy makers, funders, governmental officials, and representatives from international organisations (including WHO) and from the industry. The foremost target groups for the conference are the EU Commission, the EU-US Task force on Antimicrobial Resistance and the WHO.

Activities of Ursula Theuretzbacher during the ICAAC 2010 in Boston, MA:

• Symposium “Novel Antibacterial Agents by Licensing: what Big Pharma wants and what Small Biotech can offer"
  U. Theuretzbacher: "What’s on the shelf: The biotech pipeline of novel antibiotics". Abstract
  Sept. 12, 4:00:00 - 6:00 PM, room 258A
• Chair: Symposium "Penetration of Anti-Infective Agents"
  Sept. 15, 8:30:00 - 10:30:00 AM, 210A
• ISAP Workshops, Boston, MA
  Sept. 11, 9:00 am - 4:30 pm, Westin Boston Waterfront Hotel:
  - Preclinical Pharmacokinetics and Pharmacodynamics of Anti-infective Agents
  - Clinical Relevance of Pharmacokinetics and Pharmacodynamics of Anti-infective Agents
• ISAP Post-ICAAC Symposium, Boston, MA
  September 15th, 2:00-6:00 pm, Westin Boston Waterfront Hotel
  Program:PK/PD in special sites of infection - TB drugs
  - Brief introduction to M. tuberculosis-infection (U. Theuretzbacher
  - Studying PK/PD of TB drugs - A daunting challenge (C. Peloquin)
  - Young investigator presentations (PK/PD of TB drugs and general PK/PD): 10 min presentations

Ursula Theuretzbacher has been invited to present at the 7th Annual Anti-Infectives Partnering & Deal-Making Summit, Oct 7-8, 2010 in Boston, MA
The Global Need for New Antibiotics – International Actions and Implications for Antibacterial Drug Development

The pandemic of multi-drug resistant pathogens and their continuing spread is beyond dispute. Driven by concern regarding this rapidly worsening global health crisis and the confounding lack of robust drug pipelines, several multinational campaigns have initiated broad discussion and put action plans in place. In an impressive show of international interest, the ECDC, EMEA, WHO, and the US government, as well as the IDSA and several other large non-profit organizations, are addressing the global problem by bringing attention and focus to the problematic and systemic paucity of new antibiotics to combat drug-resistant bacteria.
• What are the predictions for future resistance development trends?
• How would the action plans influence the antibacterial R&D business?
• What are the challenges and opportunities arising from international action plans?

Ursula Theuretzbacher has been invited to present at the 2nd Anti-Infectives Summit
September 27 - 29, 2010, San Francisco, CA

Multi-Drug Resistance As A Driver In The Development Of New Drugs

The development of drug resistance limits the effectiveness of many anti-infectives. The changing face of the disease, emergence of more resistant strains and changes in patterns of infection all add to the risks assumed by a pharmaceutical company investing in the development of an antiviral therapeutic. Managing risks is an important part of survival in heavily competitive spaces. Only the fit firms with compelling cases for drug effectiveness survive. Topics to be discussed include:

* Major patterns of drug resistance
* Risks associated with multi-drug resistant pathogens
* Techniques used to maximize effectiveness of therapeutics against resistance

A new review has been published:
Li, Yanjun; Theuretzbacher, Ursula; Clancy, Cornelius J.; Nguyen, M. Hong; Derendorf, Hartmut: Pharmacokinetic/Pharmacodynamic Profile of Posaconazole. Clin Pharmacokin 2010, 49 (6) 379-396

Ursula Theuretzbacher and Johan Mouton founded the ESCMID PK/PD of Anti-Infectives Study Group (EPASG). The inaugural meeting will take place during the ECCMID on April 10, 2010 at 17.30 - 18.30 in meeting room G 631/H632 (Vienna Conference Center) in Vienna, Austria

Activities of Ursula Theuretzbacher during the ECCMID 2010 in Vienna, Austria

• ISAP/EPASG workshop
• Inaugural meeting of EPASG
• Poster presentation at European Network Corner
• Official symposium at ECCMID:
  Role of pharmacokinetics in early stages of antimicrobial development
• Post-ECCMID ISAP/EPASG symposium

Ursula Theuretzbacher has been invited to present at the

16th Symposium of the Immunocompromised Host Society, 27-30 June 2010, Budapest, Hungary

Antimicrobial PK-PD Issues for Cancer Patients (Abstract)

A comprehensive review of pharmacokinetic and pharmacodynamics considerations of antimicrobial agents given to the immunosuppressed cancer and transplant patients. A tale beyond drug-drug interaction and clearance.

Executive Briefing presented by the Center for Anti-Infective Agents (CEFAIA)

Mark your calendar as the dates have been set for the 3rd Antibacterial Market Executive Briefing. Join us on November 1st, 14:00 to 18:00, in Vienna, Austria.

Challenges in the antibacterial market
Moving out of survival mode

Information and registration

On behalf of ISAP Ursula Theuretzbacher has organized the Post-ICAAC symposium in San Francisco

Ursula Theuretzbacher has been invited to participate in the Educational Workshop in cooperation with the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco 2009, USA

Preclinical Pharmacokinetics and Pharmacodynamics of Anti-infective Agents

Clinical Relevance of Pharmacokinetics and Pharmacodynamics of Anti-infective Agents

The review about the future of antibiotics has been published:

Ursula Theuretzbacher: Future antibiotics scenarios: is the tide starting to turn?
International Journal of Antimicrobial Agents: Volume 34, Issue 1, Pages 15-20

Ursula Theuretzbacher will present at the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

16-19th May 2009, Helsinki, Finnland

Educational workshop:
Pharmacokinetics and pharmacodynamics of anti-infective agents.

U. Theuretzbacher has been invited to present at the

6th Anti-Infectives Partnering & Deal-Making Summit
March 5-6, 2009, Boston, MA

Diagnostics Team Up with Narrow-Spectrum Antibiotics: Synergistic Business Opportunities and Evolving Trends

The development of narrow-spectrum or single pathogen–only antibiotics is increasingly seen as attractive niche market opportunities. Resistance challenges, antibiotic control programs in hospitals, escalating health care costs, long development time lines, regulatory environment challenges, and dry pipelines, power the trend to more targeted therapies. Driven by the principles of personalized medicine, the hospital point-of care rapid diagnostic market promises dramatic market expansion via improved and rapid tests that are reliable and easy to integrate into hospital routine. Diagnostic-therapeutic co-development and early partnerships will be important drivers for targeting the clinical trial population and accessing markets more rapidly and efficiently. This overview discusses
• Existing examples for diagnostic-therapeutic partnerships
• Strategies for the clinical development phase
• Regulatory opportunities and pitfalls
• Synergistic strategies for diagnostic and drug development companies in the market

U. Theuretzbacher has been invited to present at the

Re-emerging Infectious Diseases conference
11th -12th December 2008, London UK

Cultural implications for antibacterial drug development and usage
• Differences in general perception of medicine and antibiotic usage in US vs EU
• Medical need – everywhere the same?
• Cultural implications regarding drug development and commercialization strategies in US vs EU

U. Theuretzbacher has been invited to participate in the Educational Workshop in cooperation with the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington D.C. 2008, USA

Preclinical Pharmacokinetics and Pharmacodynamics of Anti-infective Agents

Clinical Relevance of Pharmacokinetics and Pharmacodynamics of Anti-infective Agents

Mark your calendar as the dates have been set for the Executive Briefing November 16th, 14:00 to 18:00 in Mannheim, Germany

Optimising partnering strategies in the anti-infectives market
The comeback of the antibacterial business

Information and registration

U. Theuretzbacher has been invited to present at the

2nd World Conference on Magic Bullets (Ehrlich II) in Nürnberg, Germany, October 3 - 5, 2008

Oral presentation:
Evaluating our performance: Tissue penetration paradigm shift
Abstract

PK/PD workshop

The leading article about tissue concentrations has been published:

Mouton JW, Theuretzbacher U, Craig WA, Tulkens PM, Derendorf H, Cars O: Tissue concentrations: do we ever learn?
J Antimicrob Chemother. 2008;61(2):235-7

Ursula Theuretzbacher will present at the 18th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID):

• Educational workshop:
  Pharmacokinetics and pharmacodynamics of anti-infective agents. Handout
• Meet-the-Expert session:
  What is the role of PK/PD in the management of fungal infections? How to handle in the everyday life?
• Symposium:
  Antibiotic stewardship in the ICU: today and tomorrow

The review about PK/PD has been published:

Ursula Theuretzbacher: Tissue penetration of antibacterial agents: how should this be incorporated into pharmacodynamic analyses? Current Opinion in Pharmacology 2007, 7:498–504

U. Theuretzbacher has been invited to present at 11th International Symposium
"Current Topics in Infectious Diseases"
January 27 - February 1, 2008

Antibiotics: what’s new and what’s in the pipeline?

U. Theuretzbacher has been invited to present at FDA in Washington DC, Division of Pharmaceutical Evaluation III, Oct 22nd, 2007

The Influence of Tissue Distribution and Protein Binding on Resistance.

Abstract

U. Theuretzbacher has been invited to participate in the APUA 2nd world congress in Boston, Oct 29-30th, 2007

Symposium "Future Strategies in Drug Development and Prescribing"

Robert C. Moellering, MD, Beth Israel Deaconess Medical Center, Harvard Medical School — “New concepts of anti-infective therapy” — Tentative
• Ian Gould, PhD, MBChB, FRCPE, FRCPath , Consultant Microbiologist, Aberdeen Royal Infirmary, UK — “Unintended consequences of prescribing
policies”
• Dominique L. Monnet, PharmD, PhD, Statens Serum Institut, Denmark — “Encouraging development of new antibacterials while preserving the old”
• Ursula Theuretzbacher, PhD, Center for Anti-Infective Agents — “Antimicrobials in the future”
• Steven J. Projean, PhD, Biological Technologies, Wyeth Research — “How can we control antibiotic resistance when we don’t understand it?”

U. Theuretzbacher has been invited to run the Executive Briefing following the smi-conference Superbugs & Superdrugs in London, 23rd to 24th April 2007

This Executive Briefing will explore the biggest issues in antibacterial resistance looking in-depth at the current market and forward 10 years into the future. Attendees will explore the resistance problem and examine the current R&D pipeline.

Report: Resisting the call for new antibacterials?

U. Theuretzbacher has been invited to present at the 4th Anti-Infectives Partnering & Deal-Making Summit - Jan. 25-26, 2007, San Francisco, USA

U. Theuretzbacher has been invited to participate in the ISC working session: Reconciling the goals of antibiotic policy and drug development.
17th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) and 25th International Congress of Chemotherapy (ICC), Munich/Germany, 31 March - 3 April 2007
Symposium, jointly organised by the ISC Working Group on Future Antimicrobials and the ESCMID Study Group on Antibiotic Policies

Conveners: Jean Claude Pechère, Geneva, CH
Inge C. Gyssens, Rotterdam, NL

Topics:
Antimicrobials in the future
New concepts of anti-infective therapy
Optimal strategies for use of new antimicrobials
Panel discussion

Faculty: Ursula Theuretzbacher, Vienna, AT
Robert C. Moellering, Boston, US
Dominique L. Monnet, Copenhagen, DK
Michael M. Dudley, San Diego, US
William A. Craig, Madison, US
Ian Gould, Aberdeen, UK

U. Theuretzbacher has been invited to present at the 8th European Conference of Chemotherapy in Budapest, Oct 25-28, 2006

Abstract

The review about the pharmacokinetics and pharmacodynamics of voriconazole has been published:

U. Theuretzbacher, F. Ihle, H. Derendorf: Pharmacokinetic/Pharmacodynamic Profile of Voriconazole. Clin Pharmacokinet 2006; 45 (7): 649-663

Abstract

U. Theuretzbacher is chairing the working group of the International Society of Chemotherapy (ISC): Antimicrobials of the Future

Some ideas

The review about the future of antibiotics has been published:

U. Theuretzbacher, J. Toney: Nature's clarion call of antibacterial resistance: are we listening? Curr Opin Investig Drugs. 2006 Feb;7(2):158-66.

Abstract

U. Theuretzbacher has been invited to present at the Annual Conference on Antimicrobial Resistance - June 26-28, Bethesda, USA

U. Theuretzbacher has been invited to participate in the Educational Workshop of ISAP (International Society of Anti-Infective Pharmacology) in cooperation with the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Nice 2006, France

U. Theuretzbacher has been invited to present at the 3rd Anti-Infectives Partnering & Deal-Making Summit - Jan. 26-27, San Diego, USA

Abstract

ISAP (International Society of Anti-Infective Pharmacology) Educational Workshop
in cooperation with the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington 2005, USA

Introduction to PK/PD
H. Derendorf, PhD
Department of Pharmaceutics, University of Florida, Gainsville, FL

PK/PD indices
J. Mouton, MD, PhD
Canisius Wilhelmina Hospital, Nijmegen, The Netherlands

Protein binding, tissue distribution
U. Theuretzbacher
Center for Anti-Infective Agents, Vienna, Austria

In vitro models
I. Odenholt, MD
Departement of Infectious Diseases, Malmö University Hospital, Malmö, Sweden

Animal models
W.A. Craig,
Division of Infectious Diseases, University of Wisconsin, Madison, WI

In vitro resistance
O. Cars,
Division of Infectious Diseases, University Hospital, Uppsala, Sweden

U. Theuretzbacher has been invited to participate in the symposium Clinical Issues of PK/PD organized by the
European Congress of Chemotherapy and Infection (ECC), Florence, Italy

Abstract

Clinical Issues of PK/PD
Chairmen: W.A. Craig (USA) - F. Scaglione (Italy)
Thursday, October 20th 2005, 14.30 - 16.00
• PK/PD in special populations (H. Derendorf, USA)
• Clinical implications of tissue concentrations (U. Theuretzbacher, Austria)
• Clinical implications and recommendations based on PK/PD relationships (J.W. Mouton, The Netherlands)
• Role of clinical pharmacologists in the PK/PD aera (G.L. Drusano)

The review about beta-lacatamases has been published:

U. Theuretzbacher: Beta-Lactamases and Beta-Lactamase Inhibitors - an update. Chemotherapie-Journal 2004 (13) 5

The review about PK/PD of Echinocandins has been published online:

U. Theuretzbacher: Pharmacokinetics/Phamacodynamics of Echinocandins. European Journal of Clinical Microbiology and Infectious Diseases 2004, published online: 14 October 2004

ISAP (International Society of Anti-Infective Pharmacology) Educational Workshop
in cooperation with the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington 2004, USA

World Conference on Dosing of Antiinfectives, Nürnberg, Germany
Program: Introduction to PK/PD (Derendorf)
PK/PD indices (Mouton)
Protein Binding/Tissue Distribution (Theuretzbacher)
In vitro models (Mouton)
Animal models (Craig)
In vitro resistance (Cars)

The second edition of the textbook "U. Theuretzbacher: Mikrobiologie im klinischen Alltag (Microbiology for primary care physicians and specialists) has been published and is available now. It has 800 pages and deals with all aspects of pathogens, diagnosing and treating with anti-infective agents. Doctors love it and I am getting great feed back.